Iovance Biotherapeutics

Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Iovance Biotherapeutics progresses on BLA for lifileucel, faces recruitment challenges

Iovance Biotherapeutics is on track with BLA completion expected this quarter, strong pipeline progress, and manufacturing capacity expansion. Challenges include study recruitment uncertainties and the ongoing CEO search. Opportunities exist in new program data releases, European expansion, and pivotal study enrollment.

Iovance Biotherapeutics advances TIL therapy pipeline with strong financials

Iovance Biotherapeutics is on track with key milestones in TIL therapy development and commercialization.
The company's financial position is stable, with strategic investments supporting future growth.
Challenges include operational efficiency, FDA interactions, and trial progress management.
Opportunities lie in international trials, market expansion, and revenue growth post-launch.

Iovance Biotherapeutics reports Q2 loss, eyes lifileucel FDA review

Iovance Biotherapeutics faces financial challenges with a significant net loss in Q2 2023, despite positive milestones and revenue from Proleukin sales.
The company's TIL therapy pipeline shows promise with progress in key clinical trials, while opportunities exist for market differentiation and revenue growth.
Challenges include ongoing financial losses, longer timelines for pivotal studies, and potential delays in trial enrollment, requiring strategic management.

Iovance Biotherapeutics progresses on Lifileucel commercialization and pipeline expansion

Iovance Biotherapeutics is making significant strides in advancing its pipeline and commercialization efforts, with a strong focus on FDA approval for Lifileucel and expanding into key markets. The company faces challenges in labeling discussions and efficacy benchmarks but has opportunities in European marketing, new therapy programs, and potential partnerships for international growth.

Iovance Biotherapeutics excels with Amtagvi approval and clinical progress

Iovance Biotherapeutics showcased strong performance with the FDA approval of Amtagvi and progress in clinical trials, positioning the company for growth.
While facing challenges in scaling operations and regulatory hurdles, the company's focus on efficiency and clinical research strengths bode well for the future.
With opportunities in label expansion, market penetration, and revenue growth, Iovance is poised to capitalize on its innovative therapies and drive value for stakeholders.

Iovance Biotherapeutics reports Q1 loss, Amtagvi launch success

Iovance Biotherapeutics shows promising performance with a focus on Amtagvi's commercial success and pipeline advancements.
Strengths include positive reimbursement trends, successful patient selection processes, and efficient manufacturing operations.
Challenges lie in patient screening failures, financial clearance issues, and variability in bridging therapy usage.
Opportunities for growth include market expansion, high patient conversion rates, and accelerated submission processes for new therapies.

Iovance Biotherapeutics (IOVA) exceeds Q3 revenue targets, eyes global expansion

Iovance Biotherapeutics (IOVA) had a strong Q3 performance, exceeding revenue guidance and showcasing growth potential.
The company's focus on Amtagvi and global expansion presents opportunities for revenue diversification and market penetration.
Challenges lie in maintaining adoption rates, meeting revenue targets, and effectively managing increased manufacturing capacity.
Overall, IOVA's strategic initiatives position it for continued growth and success in the biopharmaceutical market.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Median Duration of Response Not Reached at 17.0 Months   of Median Study Follow Up in C-144-01 Study

Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma

argenx

Ascendis Pharma

Axsome Therapeutics

Amicus Therapeutics

Natera

United Therapeutics

Amid the COVID-19 pandemic, the investing pros say that it’s still possible to unmask names poised to take off on an upward trajectory.

7 “Strong Buy” Healthcare Stocks to Buy Now

Iovance's (IOVA) first-quarter loss wider than estimated. The company progressing well with its lead pipeline candidates.

Iovance (IOVA) Q1 Loss Wider Than Expected, Revenues Nil

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q1 2020 Results - Earnings Call Transcript

Gilead Sciences

Takeda Pharmaceutical

Iovance Biotherapeutics Inc. (NASDAQ:IOVA) might be even more attractive to rumored suitors after the San Francisco-area company’s cancer-fighting treatment showed promise in early testing.

Gilead, Takeda Rumored to Have Sights on Iovance

Investors need to pay close attention to Iovance Biotherapeutics (IOVA) stock based on the movements in the options market lately.

Do Options Traders Know Something About Iovance Biotherapeutics (IOVA) Stock We Don't?

Fate Therapeutics

The worst is yet to come for the stock market, but these biopharma companies have promising potential.

My Top Biotech Stocks to Buy in the Market Crash

Iovance Biotheraputics: Still Well-Poised To Treat Solid Tumors

Iovance Biotherapeutics: Buy The Dip

Are Options Traders Betting on a Big Move in Iovance Biotherapeutics (IOVA) Stock?

Rumors of a buyout swirled around the biopharma.

Here's Why Iovance Biotherapeutics Jumped 51.3% in February

Cogent Communications Holdings

Campbell Soup

Kroger

Newmont Mining

Regeneron Pharmaceuticals

iStar Inc

Virtu Financial

Vivint Smart Home Inc

The stock market in 2020 has gone from a raging bull market to panic mode in very short order.

10 Very Strong Stocks Thriving in a Very Crummy Stock Market

Iovance Biotherapeutics: There Is A Significant Upside In This Stock

Iovance Biotherapeutics, Inc. (IOVA) CEO Maria Fardis on Q4 2019 Results - Earnings Call Transcript

Bloomberg reports that the company has been toying with the idea of a sale.

Here's Why Iovance Biotherapeutics Shares Soared as Much as 39.6%

These two companies are pushing the envelope of immunotherapies by developing unique cell types. Each has promising results for investors to consider.

2 Top Biotech  Stocks to Buy Right Now

- Biologics Licensing Application (BLA) submission planned for late 2020 -

Iovance Biotherapeutics Completes Patient Dosing in Registration-Enabling Cohort 4 of the C-144-01 Melanoma Study with Lifileucel

The company announced a string of deals over the weekend that failed to spark investors' optimism.

Why Iovance Biotherapeutics Shares Dropped 11.8% Today

Shares of Iovance Biotherapeutics toppled Monday after the biotech company announced a gene-editing deal with Cellectis using TALEN technology. Cellectis stock also slipped.

Why This Biotech Stock Is Planning To Gene Edit Its Cancer Drugs

SAN CARLOS, Calif., Jan.  12, 2020  (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that the company has obtained a license from Novartis to develop and commercialize an antibody cytokine engrafted protein, referred to as IOV-3001. Under the agreement, Iovance will pay an upfront payment to Novartis as well as low single digit milestones involved in initiation of patient dosing in various phases of clinical development for IOV-3001 and approval of the product in the U.S., EU and Japan. Novartis is also entitled to low-to-mid single digit royalties from commercial sales of the product.

Iovance Biotherapeutics Obtains License to Develop and Commercialize a Novel IL-2 Analog

Iovance Biotherapeutics Will Use TALEN® Technology from Cellectis to Develop Gene-Edited TIL Iovance Biotherapeutics Will Use TALEN® Technology from Cellectis to Develop Gene-Edited TIL

Iovance Biotherapeutics and Cellectis Enter into a Research Collaboration and Exclusive Worldwide License Agreement

BioMarin Pharmaceutical

Immunomedics

Fast-approaching catalysts could make these biotech stocks top performers this year.

These 3 Biotech Stocks Could Be Top Stocks in 2020

The biopharma stock more than tripled in 2019.

Here's Why Iovance Biotherapeutics Jumped 21.2% in December

These companies are carving their own paths in cellular medicines. One just posted promising clinical results, while the other aims to do so this month.

2 Top Biotech Stocks to Buy in December

Iovance Biotherapeutics: Solving The Solid Tumors Conundrum

News for Iovance Biotherapeutics Stock (IOVA)